PARIS, October 17, 2025 AB Science S.A., a biopharmaceutical company focused on discovering, developing, and marketing protein kinase inhibitors, has announced the successful completion of a €2.8 million private placement. The financing round, conducted with select European institutional and qualified investors, strengthens the company’s financial foundation as it continues to advance its clinical programs in oncology, neurology, and inflammatory diseases. The placement underscores investor confidence in AB Science’s innovative therapeutic strategy and long-term scientific potential.
Science Significance
This financing milestone will help accelerate the ongoing research of AB Science’s lead compound masitinib, a selective tyrosine kinase inhibitor with applications across several severe diseases including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and mast cell disorders. The additional funding ensures continued progress in late-stage clinical trials that are critical to validating masitinib’s efficacy and safety profile. This reinforces AB Science’s leadership in targeted kinase inhibition, a frontier of modern biopharmaceutical science.
Regulatory Significance
The capital raised will support AB Science’s regulatory engagement with agencies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). The company aims to align its clinical documentation with Good Clinical Practice (GCP) and European regulatory standards, paving the way for future market authorization submissions. The private placement reflects AB Science’s readiness to meet the stringent compliance and data integrity requirements for approval in multiple therapeutic indications.
Business Significance
Advertisement
The €2.8 million private placement marks a strategic financial achievement for AB Science, enabling the company to fortify its liquidity and sustain development operations without over-reliance on debt. The offering’s success demonstrates strong market trust in the company’s drug pipeline, particularly masitinib’s commercial potential in high-impact diseases. These funds will also contribute to operational expansion, reinforcing AB Science’s position in Europe’s growing biopharma innovation landscape.
Patients’ Significance
For patients battling neurodegenerative and inflammatory diseases, this financing provides renewed optimism. With enhanced funding, AB Science can maintain trial continuity and move promising therapies closer to market readiness. The company’s patient-centered mission—to deliver targeted, effective, and safe treatments for unmet medical needs—is directly supported by this capital infusion, potentially accelerating access to next-generation therapies that improve quality of life and survival outcomes.
Policy Significance
The private placement aligns with European health innovation policies encouraging the development of advanced therapeutic platforms addressing chronic and rare diseases. AB Science’s funding success also reflects the European Union’s supportive stance on private investments in biotech research. The move emphasizes how financial and policy ecosystems are jointly fostering biopharmaceutical growth, scientific excellence, and healthcare accessibility across the EU.
The successful €2.8 million private placement marks another milestone in AB Science’s journey to transform the treatment landscape for complex neurological and inflammatory diseases. By combining scientific rigor with strategic financial management, the company is positioned to advance its clinical pipeline, achieve key regulatory milestones, and deliver breakthrough therapies to patients in need. This development reinforces AB Science’s vision to lead the next generation of innovative, targeted biopharmaceuticals with global impact.
Source: AB Science Press Release
